S Teckie1,2,3, S Qi1,4, M Chelius1, S Lovie1, M Hsu5, A Noy6,7, C Portlock6,7, J Yahalom1,7. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York. 2. Department of Radiation Medicine, Northwell Health, New York. 3. Hofstra Northwell School of Medicine, Hempstead, USA. 4. Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 5. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York. 6. Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York. 7. Weill Cornell Medical College, New York, USA.
Abstract
BACKGROUND: Localized early-stage extra-nodal marginal zone lymphoma (MZL) presents with heterogeneous organ involvement and is treated with various modalities, including resection, radiotherapy, and systemic therapy. We report the long-term outcome of a large cohort of extra-nodal MZL and assess the impact of patient and disease characteristics, organ site, and treatment strategy on disease control and survival. PATIENTS AND METHODS: We identified 487 consecutive patients with stage IE or IIE MZL referred between 1992 and 2012 to Memorial Sloan Kettering Cancer Center. Pathology was reviewed by hematopathologists at our institution. Patient and disease factors as well as treatment types were analyzed for association with relapse-free survival, overall survival, and cumulative incidence of relapse. RESULTS: Median follow-up after treatment was 4.7 years. Five-year relapse-free survival and overall survival were 60% and 89%, respectively. Cumulative incidence of disease-specific death at 5 years was 1.3%. Radiotherapy alone was the initial treatment in 50% of patients, followed by surgical resection (30%), observation (8%), immunotherapy (4%), and chemotherapy (2%). Initial treatment type, primary disease site, and number of involved sites were significant factors in multivariable analysis of relapse (all P < 0.05). When compared with stomach, MZL originating in other disease sites (HR > 2.0, P ≤ 0.001), except for thyroid, had higher risk of relapse. Strategies such as antibiotics or topical therapies were associated with higher risk of relapse when compared with radiation therapy (P < 0.001). Crude rate of transformation to pathologically confirmed large-cell lymphoma was 2% (11 patients). CONCLUSION: Overall and cause-specific survival are high in early-stage extra-nodal MZL. Curative-intent treatment led to fewer relapses and reduced the need for salvage. Stomach cases had lower risk of relapse than other anatomic primary sites. This study supports the use of local therapies to treat stage IE and IIE MZL.
BACKGROUND: Localized early-stage extra-nodal marginal zone lymphoma (MZL) presents with heterogeneous organ involvement and is treated with various modalities, including resection, radiotherapy, and systemic therapy. We report the long-term outcome of a large cohort of extra-nodal MZL and assess the impact of patient and disease characteristics, organ site, and treatment strategy on disease control and survival. PATIENTS AND METHODS: We identified 487 consecutive patients with stage IE or IIE MZL referred between 1992 and 2012 to Memorial Sloan Kettering Cancer Center. Pathology was reviewed by hematopathologists at our institution. Patient and disease factors as well as treatment types were analyzed for association with relapse-free survival, overall survival, and cumulative incidence of relapse. RESULTS: Median follow-up after treatment was 4.7 years. Five-year relapse-free survival and overall survival were 60% and 89%, respectively. Cumulative incidence of disease-specific death at 5 years was 1.3%. Radiotherapy alone was the initial treatment in 50% of patients, followed by surgical resection (30%), observation (8%), immunotherapy (4%), and chemotherapy (2%). Initial treatment type, primary disease site, and number of involved sites were significant factors in multivariable analysis of relapse (all P < 0.05). When compared with stomach, MZL originating in other disease sites (HR > 2.0, P ≤ 0.001), except for thyroid, had higher risk of relapse. Strategies such as antibiotics or topical therapies were associated with higher risk of relapse when compared with radiation therapy (P < 0.001). Crude rate of transformation to pathologically confirmed large-cell lymphoma was 2% (11 patients). CONCLUSION: Overall and cause-specific survival are high in early-stage extra-nodal MZL. Curative-intent treatment led to fewer relapses and reduced the need for salvage. Stomach cases had lower risk of relapse than other anatomic primary sites. This study supports the use of local therapies to treat stage IE and IIE MZL.
Authors: Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl Journal: J Clin Oncol Date: 2007-01-22 Impact factor: 44.544
Authors: Ali Mazloom; L Jeffrey Medeiros; Peter W McLaughlin; Valerie Reed; Fernando F Cabanillas; Luis E Fayad; Barbara Pro; Graciela Gonzalez; Puneeth Iyengar; Diana L Urbauer; Bouthaina S Dabaja Journal: Cancer Date: 2010-09-15 Impact factor: 6.860
Authors: Markus Raderer; Berthold Streubel; Stefan Woehrer; Andreas Puespoek; Ulrich Jaeger; Michael Formanek; Andreas Chott Journal: Clin Cancer Res Date: 2005-05-01 Impact factor: 12.531
Authors: Jayant S Goda; Mary Gospodarowicz; Melania Pintilie; Woodrow Wells; David C Hodgson; Alexander Sun; Micheal Crump; Richard W Tsang Journal: Cancer Date: 2010-08-15 Impact factor: 6.860
Authors: Richard W Tsang; Mary K Gospodarowicz; Melania Pintilie; Woodrow Wells; David C Hodgson; Alexander Sun; Michael Crump; Bruce J Patterson Journal: J Clin Oncol Date: 2003-11-15 Impact factor: 44.544
Authors: Chelsea C Pinnix; Jillian R Gunther; Sarah A Milgrom; Ruben J Cruz Chamorro; L Jeffrey Medeiros; Joseph D Khoury; Behrang Amini; Sattva Neelapu; Hun J Lee; Jason Westin; Nathan Fowler; Loretta Nastoupil; Bouthaina Dabaja Journal: Int J Radiat Oncol Biol Phys Date: 2019-02-12 Impact factor: 7.038
Authors: Gabriele Reinartz; Regina P Pyra; Georg Lenz; Rüdiger Liersch; Georg Stüben; Oliver Micke; Kay Willborn; Clemens F Hess; Andreas Probst; Rainer Fietkau; Ralf Jany; Jürgen Schultze; Christian Rübe; Carsten Hirt; Wolfgang Fischbach; Martin Bentz; Severin Daum; Christiane Pott; Markus Tiemann; Peter Möller; Andreas Neubauer; Martin Wilhelm; Normann Willich; Wolfgang E Berdel; Hans T Eich Journal: Strahlenther Onkol Date: 2019-03-11 Impact factor: 3.621
Authors: Barbara Kiesewetter; Wolfgang Lamm; Werner Dolak; Julius Lukas; Marius E Mayerhoefer; Michael Weber; Ana-Iris Schiefer; Christoph Kornauth; Günther Bayer; Ingrid Simonitsch-Klupp; Markus Raderer Journal: Br J Haematol Date: 2019-05-24 Impact factor: 6.998
Authors: Barbara Kiesewetter; Wolfgang Lamm; Ortrun Neuper; Marius E Mayerhoefer; Ingrid Simonitsch-Klupp; Markus Raderer Journal: Hematol Oncol Date: 2019-07-28 Impact factor: 5.271
Authors: Melissa Lumish; Lorenzo Falchi; Brandon S Imber; Michael Scordo; Gottfried von Keudell; Erel Joffe Journal: J Hematol Oncol Date: 2021-01-06 Impact factor: 17.388
Authors: Barbara Kiesewetter; Ingrid Simonitsch-Klupp; Marius E Mayerhoefer; Werner Dolak; Julius Lukas; Markus Raderer Journal: Cancers (Basel) Date: 2020-11-26 Impact factor: 6.639
Authors: Marzia Cerrato; Erika Orlandi; Angelisa Vella; Sara Bartoncini; Giuseppe C Iorio; Diego Bongiovanni; Francesco Capriotti; Carola Boccomini; Francesco Vassallo; Chiara Cavallin; Viola De Luca; Francesca R Giglioli; Umberto Ricardi; Mario Levis Journal: Br J Radiol Date: 2021-06-16 Impact factor: 3.039